Company news

Alterity Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Form 20-F

September 3, 2021

Appendix 4E & Annual Report 2021

August 31, 2021

New US Patent Expands Neurodegeneration Treatment Portfolio

August 4, 2021

New Publication Demonstrates ATH434 is Neuroprotective

July 15, 2021

New US patent targeting major neurodegenerative diseases

July 1, 2021

EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial

June 23, 2021

ATH434 protects brain cells and improves motor function

April 21, 2021

Alterity to present at Global Life Science Conference

March 10, 2021

Michael J Fox grant for Parkinsons research on ATH434

February 8, 2021

Alterity participates in JP Morgan healthcare conference

January 11, 2021

Dr David Stamler Appointed CEO

January 6, 2021

Form F-3

December 23, 2020

New commercial opportunity for PBT2

December 21, 2020

Alterity presents at Finance News Network

December 1, 2020

Prospectus filed pursuant to SEC Rule 424(b)(3)

November 24, 2020

Chairmans Address 2020 Annual General Meeting

November 17, 2020

US patent for next generation neurodegenerative diseases

November 15, 2020

MSA patients enrolled in bioMUSE Study

October 26, 2020

Alterity completes Placement Tranche 1 raising $10M

October 23, 2020

Alterity raises $35M in placement to institutional investors

October 15, 2020

Company update on Annual Report 2020

September 9, 2020

Preliminary Final Report

August 30, 2020

New data independently confirms safety profile of ATH434

August 4, 2020

Pause in Trading

July 1, 2020

Meeting with US FDA provides development path for ATH434

June 30, 2020

Presentation on ATH434 to American Academy of Neurology

May 20, 2020

Appendix 4C and Quarterly Update

April 30, 2020

NASDAQ Temporary Relief

April 22, 2020

NASDAQ Non-Compliance Notice Received

February 7, 2020

Appendix 4C - quarterly

January 31, 2020

Alterity receives a $4.8 million R&D Tax Incentive Refund

January 14, 2020

European Orphan Designation granted for PBT434 for MSA

January 13, 2020

AGM Presentation 2019

November 25, 2019

Chairmans Address to Shareholders

November 25, 2019

Lead drug candidate receives positive opinion from EMA

November 18, 2019

Appendix 4E & Annual Report 2019

August 30, 2019

Successful Completion of Phase 1 Clinical Trial

July 29, 2019

Alterity presents initial Phase 1 clinical trial data at AAN

May 6, 2019

Prana receives A$3.3 million R&D Tax Incentive Refund

March 18, 2019

Orphan Designation for PBT434 for treatment of MSA

January 30, 2019

Life Bioscience LLC leads strategic investment upto A$44.5M

December 27, 2018

New data show potential for PBT434 to treat MSA

October 5, 2018

Annual Report to shareholders

August 31, 2018

Prana to present PBT434 data at International Congress

July 8, 2018

First Volunteers Dosed in Phase I Clinical Trial of PBT434

July 3, 2018

Prana to commence Phase 1 clinical trial of PBT434

June 13, 2018

PBT434 at the 6th International Multiple System Atrophy Conf

March 6, 2018

Prana receives $3 million R&D Tax Incentive Refund

December 18, 2017

Prospectus Supplement

November 8, 2017

Notice of Meeting/ Proxy Form

October 13, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 47 decks. Every deck is listed under its year.